845 related articles for article (PubMed ID: 33037004)
1. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs).
Spagnolo P; Distler O; Ryerson CJ; Tzouvelekis A; Lee JS; Bonella F; Bouros D; Hoffmann-Vold AM; Crestani B; Matteson EL
Ann Rheum Dis; 2021 Feb; 80(2):143-150. PubMed ID: 33037004
[TBL] [Abstract][Full Text] [Related]
2. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
3. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
Wollin L; Distler JHW; Redente EF; Riches DWH; Stowasser S; Schlenker-Herceg R; Maher TM; Kolb M
Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31285305
[TBL] [Abstract][Full Text] [Related]
4. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
Makino S
Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
[TBL] [Abstract][Full Text] [Related]
5. Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases.
Fischer A; Distler J
Clin Rheumatol; 2019 Oct; 38(10):2673-2681. PubMed ID: 31423560
[TBL] [Abstract][Full Text] [Related]
6. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?
de Lauretis A; Veeraraghavan S; Renzoni E
Chron Respir Dis; 2011; 8(1):53-82. PubMed ID: 21339375
[TBL] [Abstract][Full Text] [Related]
7. Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications.
Erre GL; Sebastiani M; Manfredi A; Gerratana E; Atzeni F; Passiu G; Mangoni AA
Drugs Context; 2021; 10():. PubMed ID: 33505482
[TBL] [Abstract][Full Text] [Related]
8. Endotype-phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease.
Hoffmann-Vold AM; Weigt SS; Saggar R; Palchevskiy V; Volkmann ER; Liang LL; Ross D; Ardehali A; Lynch JP; Belperio JA
EBioMedicine; 2019 Dec; 50():379-386. PubMed ID: 31732480
[TBL] [Abstract][Full Text] [Related]
9. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Magnusson MO; Freiwald M
Respir Med; 2021; 180():106369. PubMed ID: 33798871
[TBL] [Abstract][Full Text] [Related]
10. Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): Evolving concept of CT findings, pathology and management.
Yoo H; Hino T; Hwang J; Franks TJ; Han J; Im Y; Lee HY; Chung MP; Hatabu H; Lee KS
Eur J Radiol Open; 2022; 9():100419. PubMed ID: 35445144
[TBL] [Abstract][Full Text] [Related]
11. Fibrosing interstitial lung diseases: knowns and unknowns.
Cottin V; Wollin L; Fischer A; Quaresma M; Stowasser S; Harari S
Eur Respir Rev; 2019 Mar; 28(151):. PubMed ID: 30814139
[TBL] [Abstract][Full Text] [Related]
12. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Sarr C; Freiwald M
BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence.
Richeldi L; Varone F; Bergna M; de Andrade J; Falk J; Hallowell R; Jouneau S; Kondoh Y; Morrow L; Randerath W; Strek M; Tabaj G
Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578333
[TBL] [Abstract][Full Text] [Related]
14. Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: Where do we stand?
Elhai M; Avouac J; Allanore Y
Semin Arthritis Rheum; 2020 Jun; 50(3):480-491. PubMed ID: 32089354
[TBL] [Abstract][Full Text] [Related]
15. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
[TBL] [Abstract][Full Text] [Related]
16. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis.
Olson AL; Patnaik P; Hartmann N; Bohn RL; Garry EM; Wallace L
Adv Ther; 2021 Jul; 38(7):4100-4114. PubMed ID: 34156606
[TBL] [Abstract][Full Text] [Related]
18. Management of Fibrosing Interstitial Lung Diseases.
Maher TM; Wuyts W
Adv Ther; 2019 Jul; 36(7):1518-1531. PubMed ID: 31119691
[TBL] [Abstract][Full Text] [Related]
19. Association between Pepsin in Bronchoalveolar Lavage Fluid and Prognosis of Chronic Fibrosing Interstitial Lung Disease.
Kim Y; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
Tohoku J Exp Med; 2018 Nov; 246(3):147-153. PubMed ID: 30405002
[TBL] [Abstract][Full Text] [Related]
20. [Use of antifibrotic drugs in interstitial lung disease].
Kreutz CP; Gesierich W; Behr J; Kneidinger N
Dtsch Med Wochenschr; 2022 Oct; 147(21):1383-1390. PubMed ID: 36279864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
